Living in Zahraa El Maadi: what happens in the first 12 weeks?
If you live in Zahraa El Maadi and are thinking about Mounjaro or Wegovy, the practical question is not only which medicine, but what happens in the first 12 weeks and how you will be followed. This article lays out the first three months as a sequence of visits: a first assessment, early follow-up of symptoms and fluids, then a review of the weight trend and eating. It contains no doses and no escalation schedules, because the dose is the treating doctor's decision, based on the product label and your condition [1, 2, 3, 4].
The La Rose branch is in New Maadi at 14 El-Mokhtar Street, off El-Nasr Street, behind QNB Bank. It is about 7 km from Zahraa El Maadi, roughly 11 minutes by car according to the recorded road measurements, which can change with traffic. Dr Shimaa Fouad, a physician and specialist in clinical and therapeutic nutrition, sees patients in Maadi on Saturday, Monday and Tuesday from 3 to 8 pm. The general picture of eligibility and the assessment is in the article "Mounjaro and Wegovy in Maadi", and this article concentrates on what comes after the start [5, 8].
Follow-up here is not a promise of a prescription. These medicines work alongside suitable eating and physical activity, and the plan may end with nutrition and activity without injections if the benefit does not outweigh the risk [1, 2, 8].
The first visit: what to bring and what is reviewed
The first visit is the baseline against which the rest of the 12 weeks is compared. Bring a list of all your medicines and supplements, your most recent tests, and any reports about diabetes, blood pressure, thyroid, kidneys, gallbladder or pancreas. The doctor will ask about personal and family history, specifically medullary thyroid carcinoma or MEN 2, because the labels treat them as contraindications to these medicines [3, 4, 5].
Pregnancy, pregnancy plans and breastfeeding are also covered. Official pages say these medicines are not used in pregnancy or while breastfeeding, that pregnancy plans should be discussed early with the doctor, and that Mounjaro may reduce the effectiveness of hormonal contraception, so ask what suits you [5, 6, 7].
Starting measurements are then recorded: weight, height, BMI and waist circumference. InBody is available at the Maadi branch when it will help the decision. The European authorised range for weight management in adults is a BMI of 30 or more, or 27 to under 30 with a weight-related condition such as raised blood pressure, abnormal lipids or sleep apnoea. This is a starting point for discussion, not an automatic decision, and the doctor also reviews your previous efforts and your ability to attend follow-up [1, 2, 8].
Mounjaro or Wegovy: what shapes the choice?
Mounjaro is a brand of tirzepatide and Wegovy is a brand of semaglutide. In Europe, both are authorised for weight management alongside a reduced-calorie diet and physical activity, and Wegovy is also authorised for adolescents aged 12 and over under specific conditions. Mounjaro also has an indication in type 2 diabetes [1, 2]. This does not mean one is better for everyone. The two main trials, SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, were separate studies and average weight change in them differs by duration and dose, so the figures should not be compared as if they were a promise [3, 4, 12, 13].
The choice in clinic depends on your situation: diabetes or blood pressure, your current medicines, pregnancy history or plans, how well you tolerate digestive symptoms, and which registered product can be bought from a licensed pharmacy. If you have questions about the differences, the article "differences between Ozempic, Wegovy and Mounjaro" explains them in detail [1, 2, 3, 4].
Do not assume the better-known name is the better fit. This article makes no claim that any particular product is currently in stock in the Egyptian market; that is confirmed at the time of prescription with a licensed pharmacy. Do not switch between the two products or combine them on your own [3, 4, 9].
Weeks 1 to 4: watching symptoms and fluids, not the scale
In the first weeks, digestive symptoms matter more than the number on the scale. Official pages list nausea, vomiting, diarrhoea, constipation and abdominal pain as common effects, and the NHS adds tiredness, itching or redness at the injection site, and hair loss [5, 6, 7]. In the SURMOUNT-1 trial the digestive effects were mostly mild to moderate and occurred mainly during the escalation period, but that is a trial average, not a guarantee for your case [12].
At an early follow-up visit, the doctor asks how much you are eating and drinking, how often you have had vomiting or diarrhoea, constipation, dizziness, tiredness, and any reaction at the injection site. If you have diabetes, glucose readings are reviewed along with whether you use insulin or a glucose-lowering medicine, because labels and official pages warn about low blood sugar in those cases [3, 4, 6]. Alcohol can worsen nausea and vomiting, so it is best avoided [6, 7].
An important point: the first 12 weeks are often still a build-up phase, so weight in this period is not a final verdict. In the STEP 4 trial, for example, the build-up before the maintenance phase lasted 16 weeks, and in SURMOUNT-4 the open-label phase lasted 36 weeks [10, 11]. Early follow-up is about safety and tolerance, and any change in dose is the doctor's decision, not yours [3, 4, 5].
Weeks 5 to 8: eating, protein and body composition
The NIDDK says obesity medicines work best alongside healthy eating and regular physical activity, and do not replace them [8]. The STEP 4 and SURMOUNT-4 trials were both run with a diet and activity intervention, so the medicine is part of the plan, not the whole plan [10, 11]. In these weeks appetite is often lower, so the challenge is eating enough protein, fluid and fibre despite feeling full quickly.
In practice, the visit discusses smaller and more frequent meals if vomiting or fullness is troublesome, a protein source at each meal, fluids across the day, and reducing fatty or fried food if it worsens symptoms, taking your usual home cooking into account. The NHS advises a healthy balanced diet with these medicines [6, 7]. Depending on your condition, the doctor may also follow supplements or tests if intake is very low.
An InBody measurement at the Maadi branch gives a picture of fat, muscle and water, and comparing it with the first-visit reading is clearer than relying on the scale alone, because fluid, salt and the menstrual cycle can change the number from week to week. For a fuller nutrition session, see the page "nutrition doctor in Zahraa El Maadi" about the clinical nutrition service reached from Maadi [8, 11].
Weeks 9 to 12: reviewing the trend, not a final verdict
Around week 12 the first broader review takes place: weight trend, waist circumference, InBody, symptoms and whether the medicine is tolerated. Trial results were averages: in SURMOUNT-1 the mean change at 72 weeks ranged from -15% to -20.9% across the different doses, and in STEP 1 it was -14.9% at 68 weeks [12, 13]. These are long-period figures, so look for the shape of the trend rather than a specific number at week 12.
The NIDDK explains that someone who loses less than 5% of starting weight after 12 weeks on the full dose will likely stop the medicine [8]. Because the build-up takes time, the formal response assessment comes after the target dose is reached, and the doctor decides the timing and the decision. If weight is stuck, the doctor reviews actual intake, fluids, sleep, activity and accompanying medicines before concluding that the medicine is not working.
Before deciding to stop on your own, know that stopping has consequences: in SURMOUNT-4 weight returned in those switched to placebo while those who continued kept the loss, and STEP 4 showed the same pattern with semaglutide [10, 11]. A 2026 analysis of discontinuation studies estimated regain of about 1 kg per month on average and favoured early monitoring after stopping [14]. So the decision is made with the doctor, with a clear plan.
Warning signs, and who needs a different option
Do not ignore a common symptom if it becomes severe or persistent. Contact the doctor if vomiting or diarrhoea stops you drinking fluids, or if you develop marked dizziness or reduced urination. Official pages say severe, persistent abdominal pain that may travel to the back should be reported at once because of possible pancreatitis, and the same applies to gallbladder problems [5, 6, 7].
Go to emergency care immediately for swelling of the face or tongue, trouble breathing or a severe rash, which can be signs of a serious allergic reaction. Report any sudden change in vision, especially with known diabetic retinopathy. If you have diabetes and use insulin or a glucose-lowering medicine, shaking, sweating and palpitations may be low blood sugar [3, 4, 6, 7].
Some people cannot use these injections or need extra caution: a personal or family history of medullary thyroid carcinoma or MEN 2, a previous serious allergic reaction to the ingredient, current or past acute pancreatitis, and pregnancy or breastfeeding. The NHS advises stopping the medicine a set period before trying to conceive, depending on the product, so plan with the doctor [3, 4, 6, 7]. Do not stop or change a treatment the doctor has prescribed on your own; speak to the doctor first.
Where to buy: with a prescription from a licensed pharmacy
The safe answer to "where do I get the pen?" is: after assessment and a prescription when treatment is suitable, from a licensed pharmacy. The FDA explains that unapproved and compounded versions have not gone through the same review of safety, effectiveness and quality, and that it has received adverse-event reports, some requiring hospitalisation, linked to compounded semaglutide and tirzepatide [9].
It has also reported dosing errors: people measuring or injecting the wrong amount, taking more than the label, more often, or escalating faster, which led to nausea, vomiting and severe abdominal pain. It warns against any pen that arrives warm or with inadequate refrigeration, and against telehealth offers with unrealistically low prices or no licensed doctor screening you [9].
In practice: check the product name, active ingredient, concentration, expiry date and storage instructions on the pack, and do not buy from a social-media advert, a group or an individual. If anything is unclear, ask the doctor or pharmacist before injecting. La Rose provides assessment, a prescription when suitable and follow-up; we do not sell medicines and do not guarantee that any particular one is in stock [3, 4, 9].
Getting there from Zahraa El Maadi, and booking
The address is 14 El-Mokhtar Street, off El-Nasr Street, behind QNB Bank, New Maadi, Cairo. From Zahraa El Maadi the distance is about 7 km, roughly 11 minutes by car according to the recorded road measurements, and it can be longer in Maadi traffic. Dr Shimaa Fouad sees patients on Saturday, Monday and Tuesday from 3 to 8 pm, and Dr Alyaa Abu Taleb on Saturday and Monday from 2 to 7 pm. Schedules can change, so confirm the day and time when booking. To book or ask questions, use WhatsApp or call 010 4066 1893.
If you are choosing between several doctors in Maadi, the article "best Mounjaro doctor in Degla, Maadi" sets out selection criteria without treating any one place as the best for everyone; the key criterion is an assessment before prescribing and a clear follow-up plan [8, 9].
Before the visit, prepare your medicine list and test photos, write down your symptoms and questions, and bring the pack or a clear photo of it if you already use a medicine. If you have severe persistent abdominal pain, trouble breathing, swelling of the face or tongue, fainting, or continuing vomiting that stops you drinking, do not wait for the appointment; go to emergency care [5, 6, 7]. For a non-urgent concern, Book at the Maadi branch.
